Simbrinza®
Brinzolamide 1% / Brimonidine Tartrate 0.2% · ophthalmic suspension
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) TID; shake well before use
Peak IOP lowering comes 2 to 3 hours after a dose, holding mean IOP near 16 to 20 mm Hg.
Elevated IOP in open-angle glaucoma or ocular hypertension, used with other topical IOP-lowering drugs
one drop in the affected eye(s) three times daily; give other topical ophthalmic drugs at least 5 minutes apart
Adds a 3.4 mm Hg drop beyond a prostaglandin alone, taking mean diurnal IOP to 17.1 mm Hg at 6 weeks.
OFF-LABELNot in the FDA label for this product
Elevated IOP on prostaglandin analog monotherapy
1 drop BID alongside the once-daily prostaglandin analog
RCT · n=188 · no TID arm
Phase 4 randomized double-masked trial, 96 patients on BID fixed combination plus prostaglandin analog versus 92 on vehicle plus prostaglandin analog for 6 weeks: least squares mean diurnal IOP change -5.59 mmHg (95% CI -6.2 to -5.0) versus -2.15 mmHg (95% CI -2.7 to -1.6), treatment difference -3.44 mmHg (95% CI -4.2 to -2.7, P below 0.001). Ocular adverse events 21.1% versus 8.7%; the trial did not compare BID against the labeled TID regimen.
Contraindications
- Hypersensitivity to any component of this product
- Neonates and infants under 2 years of age
Ophthalmic suspension, 8 mL in a 10 mL bottle, brinzolamide 1% (10 mg/mL), brimonidine tartrate 0.2% (2 mg/mL)
Fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist. Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions. Fluorophotometric studies in animals and humans suggest that brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Peak ocular hypotensive effect is 2 to 3 hours post-dose for brinzolamide and 2 hours for brimonidine.
Warnings & Precautions
- Sulfonamide hypersensitivity: Brinzolamide is a systemically absorbed sulfonamide; fatalities have occurred from Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. If signs of serious reactions or hypersensitivity occur, discontinue immediately; sensitization may recur on re-exposure by any route.
- Corneal edema: There is an increased potential for developing corneal edema in patients with low endothelial cell counts; use caution when prescribing SIMBRINZA to this group of patients.
- Somnolence in young children: Somnolence (50-83%) and decreased alertness was seen in patients 2 to 6 years old in studies of the brimonidine tartrate component.
- Potentiation of vascular insufficiency: The brimonidine component may potentiate syndromes associated with vascular insufficiency; use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
- Severe cardiovascular disease: Brimonidine produced a mean blood pressure decrease of less than 5% at 2 hours; caution.
- Severe renal impairment: SIMBRINZA has not been specifically studied in severe renal impairment (CrCl less than 30 mL/min) and is not recommended in such patients, because brinzolamide and its metabolite are excreted predominantly by the kidney.
- Severe hepatic impairment: Brimonidine not studied in hepatic impairment; caution.
- Additive carbonic anhydrase inhibition: With oral carbonic anhydrase inhibitors, there is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition; concomitant use is not recommended.
- Increased systemic side-effect: MAO inhibitors may theoretically interfere with the metabolism of brimonidine tartrate and potentially result in an increased systemic side-effect such as hypotension; caution is advised.
- Interference with the IOP lowering effect: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine; it is not known whether concurrent use with SIMBRINZA can interfere with the IOP lowering effect. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.
- Additive or potentiating effect: The possibility of an additive or potentiating effect with CNS depressants (alcohol, opiates, barbiturates, sedatives or anesthetics) should be considered.
- Reduced blood pressure: Because brimonidine tartrate may reduce blood pressure, caution is advised with drugs such as antihypertensives and/or cardiac glycosides.
- Fatigue and drowsiness: As with other drugs in this class, SIMBRINZA may cause fatigue and/or drowsiness in some patients; caution patients who engage in hazardous activities about the potential for a decrease in mental alertness.
- Contact lens wear: The preservative, benzalkonium chloride, may be absorbed by soft contact lenses; remove lenses during instillation, and they may be reinserted 15 minutes after instillation.
- Acute angle-closure glaucoma: Not studied; management requires intervention beyond ocular hypotensive agents.
- Bacterial keratitis: Reported from contaminated multi-dose containers, mostly in eyes with concurrent corneal disease or epithelial disruption.
- Acid-base alterations: Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations, though these were not reported in the clinical trials with brinzolamide ophthalmic suspension 1%. Rare instances of acid-base alterations have occurred with high-dose salicylate therapy in patients treated with oral carbonic anhydrase inhibitors; the potential for such drug interactions should be considered in patients receiving SIMBRINZA.
Common Side Effects
The most common adverse reactions (approximately 3% to 5%) were blurred vision, eye irritation, dysgeusia, dry mouth and eye allergy. Treatment discontinuation, mainly due to adverse reactions, was 11% of SIMBRINZA patients (n=435). With brinzolamide 1% alone, blurred vision and bitter, sour or unusual taste occurred in 5% to 10%, and dry eye, ocular keratitis and blepharitis in 1% to 5%. With brimonidine 0.2% alone, reactions in approximately 10% to 30% included oral dryness, ocular hyperemia, burning and stinging, headache and blurring. Postmarketing brimonidine reports include iritis, miosis and keratoconjunctivitis sicca; Stevens-Johnson syndrome and toxic epidermal necrolysis may occur with brinzolamide. Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression and somnolence have been reported in infants receiving brimonidine.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus. Oral brinzolamide in rabbits produced maternal toxicity at 120 times the ophthalmic dose and an increase in fetal variations such as accessory skull bones at 20 and 120 times, only slightly above the historical value.
Lactation: Excretion in human milk after topical ocular use is unknown; brimonidine is excreted in animal milk and radioactivity appeared in rat milk after oral brinzolamide. Because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Contraindicated under age 2.